1056 Conformal brachytherapy boost to external beam irradiation for clinically localized high risk prostate cancer

Dattoli, Michael; Wasserman, Stuart; Koval, John M.; Sorace, Richard; Cash, Jennifer; Wallner, Kent E.

doi:10.1016/0360-3016(95)97881-z

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these individuals, systemic therapy may be indicated, in addition to local therapy, if it can be demonstrated that systemic therapy is effective at preventing recurrence. Priestly and Beyer [35] 125-I 1% -1% -4% Blasko et al [63] 125-I TURP 17% Age > 70-50% 2% 7% 7% non-TURP 0% Age < 70-15% Wallner et al [57] 125-I 0% 19% 12% 0% -Blasko et al [63] XRT + 125-I TURP 13% Age > 70-50% 6% 4% 4% non-TURP 0% Age < 70-15% Kaye et al [56] 125-I ± XRT TURP 11% 25% 9% 5% 1% non-TURP 1% Dattoli et al [36] XRT + 103-PD 1% 23% -7% -Mate and Gottesman [41] XRT + 192-Ir HDR 0% --2% -a XRT ‫ס‬ external beam irradiation; HDR ‫ס‬ high dose rate brachytherapy. b TURP ‫ס‬ transureathral resection of the prostate.…”

Section: Discussionmentioning

confidence: 99%

“…This allows homogeneous dosimetry even if occasional seeds are not placed (or do not stay) in the ideal preplanned position [11]. Other centers use a peripherally weighted loading scheme with a fewer number of higher strength seeds in order to decrease the dose to the urethra in hopes of decreasing urethral complications [24,36]. With longer follow-up, we may see that the specific technique variations at different centers result in different local control rates and complication rates.…”

Section: Modern Permanent Interstitial Implantationmentioning

confidence: 94%

“…Radiation proctitis rates vary from 2% in the series of Blasko et al [61], to 12% in the series of Wallner et al Wallner et al [24] used the peripheral loading technique, which would be expected to deliver a higher dose to the anterior rectal wall than the uniform method used by Blasko et al [11], Priestly and Beyer [35], and Kaye et al [17]. Impotency rates are premature and vary somewhat among the different centers, but specifics regarding pre-implant functioning are sparse (Table IV) [35,36,41,56,57,63]. When using external beam and a permanent implant boost, the anterior rectal wall receives a higher dose than with monotherapy.…”

Section: Complications Of Brachytherapymentioning

confidence: 95%

“…There are many recent articles describing the specific techniques used by various centers [10,[35][36][37]. Some use computerized tomography (CT) guidance [24].…”

Section: Modern Permanent Interstitial Implantationmentioning

confidence: 99%

See 3 more Smart Citations

Interstitial implantation techniques in prostate cancer

et al. 1997

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Modern Permanent Interstitial Implantationmentioning

confidence: 94%

Section: Complications Of Brachytherapymentioning

confidence: 95%

“…There are many recent articles describing the specific techniques used by various centers [10,[35][36][37]. Some use computerized tomography (CT) guidance [24].…”

Section: Modern Permanent Interstitial Implantationmentioning

confidence: 99%

See 2 more Smart Citations

Interstitial implantation techniques in prostate cancer

et al. 1997

View full text Add to dashboard Cite

“…Using HDR brachytherapy (12)(13)(14)(15)(16) and EBRT (50.4 Gy), Mate et al reported that 84% of patients whose initial PSA was less than 20 ng/mL were free of progression at 5 years, based on actuarial analysis. 5 These results are quite good and similar to the effect of radical prostatectomy.…”

Section: Discussionmentioning

confidence: 99%

High‐dose rate iridium‐192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation

Chiang¹,

Fang

Jong

et al. 2004

Int J of Urology

View full text Add to dashboard Cite

Aim : To report the results of our feasibility study incorporating iridium-192 high-dose-rate (HDR) afterloading brachytherapy and external beam radiation therapy (EBRT) for the treatment of prostate carcinoma and to assess the role of androgen ablation in conjunction with this treatment option. Results : The technique of HDR brachytherapy and EBRT proved to be feasible with acceptable morbidities. Continuous prostate-specific antigen (PSA) reduction was noted in all patients and no PSA failure was noted during follow up. Within 1 year, the decline of PSA nadir values less than 1 ng/mL was faster in patients with the addition of androgen blockade ( P = 0.001). However, within 1 year, PSA nadir values less than 1.0 ng/mL can be achieved in all patients whose initial PSA is less than 20 ng/mL, with or without hormone blockade. Conclusions : The need for hormonal therapy in favorable-risk brachytherapy patients (PSA < 20 ng/ mL) might be less than the need for intermediate-or high-risk patients. The use of hormonal therapy in intermediate-risk patients (PSA ≥ 20 ng/mL) treated with HDR brachytherapy and pelvic EBRT is appealing, considering the favorable results. High dose rate brachytherapy appears to be an effective treatment for clinically localized and locally extensive prostate cancer, with minimal morbidity.

show abstract

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Ragde

Blasko

Grimm

et al. 1997

Cancer

247

View full text Add to dashboard Cite

William Cavanagh, B.S. 3 Posttherapy evaluation included clinical, biochemical (PSA), and pathologic (repeat needle biopsy) studies. No patient was surgically staged, and none received andro-1 Pacific Northwest Cancer Foundation/Northgen deprivation therapy. Morbidity was graded according to the Radiation Therapy west Hospital, Seattle, Washington.Oncology Group grading scale. Statistical appraisal was performed by the Kaplan-2 Department of Urology, University of WashMeier method. PSA failure was defined in two ways: (1) PSA progression, i.e., 2 ington, Seattle, Washington.consecutive increases from a nadir value; and (2) failure to attain an arbitrary serum PSA value of 1.0 or 0.5 ng/mL at last follow-up. 3 Department of Radiation Oncology, University RESULTS. The overall 7-year survival was 77%; there were no deaths from prostate of Washington, Seattle, Washington.carcinoma in this cohort. The 7-year actuarial PSA progression free outcome was 4 Northwest Tumor Institute, Seattle, Washing-89%, and the PSA°1.0 ng/mL outcome was 87%. When PSA°0.5 ng/mL was ton.selected as an outcome end point, and PSA values in this series of radiation-treated 5 Pathology Associates Inc., Spokane, Washingpatients were compared with PSA values proposed to indicate disease free survival ton.after radical prostatectomy (PSA°0.3-°0.6 ng/mL), the 7-year actuarial disease free survival was 79%. Morbidity was minimal except in patients who had preimplant or postimplant transurethral prostate resection. CONCLUSIONS.Outpatient-based iodine-125 prostate brachytherapy for prostate carcinoma classified as T1 or T2 resulted in biochemical outcomes comparable to end points resulting from radical prostatectomy and external beam radiation.

show abstract

1056 Conformal brachytherapy boost to external beam irradiation for clinically localized high risk prostate cancer

Cited by 13 publications

References 0 publications

Interstitial implantation techniques in prostate cancer

Interstitial implantation techniques in prostate cancer

High‐dose rate iridium‐192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Contact Info

Product

Resources

About